On May 21, 2020, Boston-based HotSpot Therapeutics announced the completion of a $65 million Series B financing. The financing round was led by SR One, Limited, and included funds managed by Tekla Capital Management, MRL Venture Fund, Solasta Ventures, and Brace Pharma, along with co-founding investors Atlas Venture and Sofinnova Partners. Wilson Sonsini Goodrich & Rosati advised SR One in the financing.

HotSpot Therapeutics is a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature’s regulatory sites. The company leverages its proprietary SpotFinder™ technology, the first and only platform designed to identify and target “regulatory hotspots,” a unique family of pockets that sit remote from the active site on a protein and are used by nature to control protein function. The company will use the financing to support the advancement of HotSpot’s lead programs to the clinic.

The Wilson Sonsini team advising SR One includes the following attorneys:

Corporate
Dan Koeppen, Partner
Meghan Burton, Associate

Patents and Innovations
Michael Hostetler, Partner
Uale Taotafa, Counsel

Regulatory/CFIUS
Joshua Gruenspecht, Partner
John Lynch, Associate

Please see HotSpot’s press release for more information.